TARA
$23.20
Artara Therapeutics
($1.22)
(5.00%)
TARA
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $0.00
Revenue:  N/A
Thursday
Feb 11
7:15 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TARA reports earnings?
Beat
Meet
Miss

Where is TARA's stock price going from here?
Up
Flat
Down
Stock chart of TARA
Analysts
Summary of analysts' recommendations for TARA
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. Protara Therapeutics Inc., formerly known as ArTara Therapeutics, is based in NEW YORK, United States.